Invest in Denmark Lifescience Cluster- Intro
•Download as PPT, PDF•
2 likes•1,163 views
The document summarizes Denmark's life science clusters and highlights its strengths as a location for life science businesses. It notes Denmark's leading positions in Europe for biotech patents and innovation. Key life science areas of strength include metabolic diseases, cancer research, and inflammatory/infectious diseases. Major companies in Denmark include Novo Nordisk. The country also has excellent research institutions, clinical trial infrastructure, and business environment and incentives.
![Reasons for establishment in Denmark ,[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
More Related Content
What's hot
What's hot (12)
Similar to Invest in Denmark Lifescience Cluster- Intro
Similar to Invest in Denmark Lifescience Cluster- Intro (20)
Recently uploaded
Recently uploaded (20)
Invest in Denmark Lifescience Cluster- Intro
- 1. Partnering Opportunities with Denmark’s Life Science Clusters – an introduction Partnering Opportunities with Denmark’s Life Science Clusters – An Introduction
- 4. Drug Development Pipeline Denmark has the 3rd largest commercial drug development pipeline in Europe (in actual numbers) (Ernst & Young 2009) Preclinical: 77 Research Phase I: 76 Phase II: 50 Phase III: 31 (Total Commercial drug development pipeline in Denmark Source: Invest in Denmark, Copenhagen Capacity 2009) Market
- 8. Metabolic Drug Development pipeline Preclinical: 3 Research: 7 Phase I: 5 Phase II: 7 Phase III: 2 (Commercial drug development pipeline in Denmark Source: Invest in Denmark, 2006) Company highlights: Novo Nordisk, Neurosearch, 7TM, Gastrotech, Rheoscience, Stevia Pharmaceuticals, Zealand Pharma etc.
- 10. Cancer Drug Development pipeline Preclinical: 16 Research: 21 Phase I: 8 Phase II: 8 Phase III: 7 (Commercial drug development pipeline in Denmark Source: Invest in Denmark, 2006) Company examples: Novo Nordisk, Leo Pharma, Genmab, Santaris Pharma, Symphogen, TopoTarget, Neurosearch, Pharmexa, Cellcure, NatImmune etc.
- 12. Inflammatory and Infectious diseases Drug Development pipeline Preclinical: 25 Research: 6 Phase I: 6 Phase II: 15 Phase III: 7 (Commercial drug development pipeline in Denmark Source: Invest in Denmark, 2006) Company examples: Leo Pharma, TopoTarget, Action Pharma, Symphogen, 7TM, Pharmexa, Novozymes, Genmab, Arpida, Ace Biosciences etc.
- 15. DENMARK / MEDICON VALLEY – ONE OF EUROPE´S STRONGEST CLUSTERS
- 16. Additional Life Science centres in Denmark Pharmaceutical production Medical Technology production R&D centres
- 18. DENMARK IS AN ECONOMIC HIGH-FLYER 08-09-09 Global Competitiveness Index (WEF) World Competitiveness Scoreboard (IMD) Innovation Capability Index (UNCTAD) Best Place to do Business (EIU) 2007-2008 2007 2005 2008-2012 1 USA USA Sweden Denmark 2 Switzerland Singapore Finland Finland 3 Denmark Hong Kong USA Singapore 4 Sweden Luxembourg Denmark Canada 5 Germany Denmark Norway Switzerland 6 Finland Switzerland Australia Australia 7 Singapore Iceland Canada Hong Kong 8 Japan Netherlands UK Netherlands 9 United Kingdom Sweden Belgium Sweden 10 Netherlands Canada Netherlands USA
- 20. Benchmark of European locations
- 22. INVEST IN DENMARK - ORGANIZATION Management Development, Marketing & Communication North America Asia Europe Life Sciences ICT Hub Danmark Renewable Energy Support Quality Assurance Creative Denmark Maritime
- 26. Danish Value Proposition Framework conditions Competences Establishment in Denmark Better drugs faster Collaborate
- 27. Regional Directors (4) New York Paris Tokyo Shanghai Investment Managers (23 in 12 locations) New York Paris Tokyo Shanghai Sillicon Valley London Taipei Toronto Munich Seoul India Hong Kong Partner missions (15) Dublin Madrid Auckland Brussels Vienna Beijing The Hague Zürich New Delhi Tel Aviv Bern Singapore Rome Milan
- 29. Thank you for your attention !